CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-31 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −422 | $141.94 | $60K | 6,309 |
| 2024-01-31 | Cooke Julie Chief Human Resources Officer | Sale 10b5-1 | −916 | $140.70 | $129K | 18,087 |
| 2024-01-31 | Cooke Julie Chief Human Resources Officer | Sale 10b5-1 | −824 | $141.94 | $117K | 17,263 |
| 2024-01-31 | Boyer David W. Chief Corp. Affairs Officer | Sale 10b5-1 | −1,104 | $140.87 | $156K | 5,886 |
| 2024-01-31 | Boyer David W. Chief Corp. Affairs Officer | Sale 10b5-1 | −992 | $140.72 | $140K | 4,894 |
| 2024-01-31 | BENEVICH ERIC Chief Commercial Officer | Sale 10b5-1 | −1,207 | $140.78 | $170K | 37,601 |
| 2024-01-31 | ABERNETHY MATT Chief Financial Officer | Sale 10b5-1 | −1,283 | $140.72 | $181K | 28,284 |
| 2024-01-22 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 | +10,000 | $79.02 | $790K | 45,882 |
| 2024-01-22 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 | −10,000 | $139.86 | $1.4M | 35,882 |
| 2024-01-22 | Lippoldt Darin Chief Legal Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −10,000 | $79.02 | $790K | 53,372 |
| 2024-01-09 | GORMAN KEVIN CHARLES Chief Executive Officer | Option exercise 10b5-1 | +62,023 | $19.59 | $1.2M | 561,777 |
| 2024-01-09 | GORMAN KEVIN CHARLES Chief Executive Officer | Sale 10b5-1 | −62,023 | $134.01 | $8.3M | 499,754 |
| 2024-01-09 | GORMAN KEVIN CHARLES Chief Executive Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −62,023 | $19.59 | $1.2M | 0 |
| 2024-01-08 | GORMAN KEVIN CHARLES Chief Executive Officer | Option exercise 10b5-1 | +105,835 | $19.59 | $2.1M | 605,589 |
| 2024-01-08 | GORMAN KEVIN CHARLES Chief Executive Officer | Sale 10b5-1 | −105,835 | $132.44 | $14.0M | 499,754 |
| 2024-01-08 | GORMAN KEVIN CHARLES Chief Executive Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −105,835 | $19.59 | $2.1M | 62,023 |
| 2024-01-02 | Gano Kyle Chief Business Development Off | Option exercise 10b5-1 | +68,884 | $19.59 | $1.3M | 199,134 |
| 2024-01-02 | Gano Kyle Chief Business Development Off | Sale 10b5-1 | −68,884 | $131.47 | $9.1M | 130,250 |
| 2024-01-02 | Gano Kyle Chief Business Development Off | Option exercise 10b5-1 | +6,116 | $19.59 | $120K | 136,366 |
| 2024-01-02 | Gano Kyle Chief Business Development Off | Sale 10b5-1 | −6,116 | $131.44 | $804K | 130,250 |
Page 40 of 49 · 963 trades